جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

9 مُخرَج نتائج البحث عن «Exacerbation»

مراجعةوصول مفتوح2026

Evaluating the therapeutic benefit of bacterial lysates in chronic obstructive pulmonary disease: a systematic review and meta-analysis

Frontiers in Medicine · مجلد 13

Background Chronic obstructive pulmonary disease (COPD) with exacerbations often triggered by infections. Bacterial lysates have been investigated as interventions to reduce the exacerbations of COPD. Methods We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating bacterial lysates (BLs) in adults with chronic obstructive pulmonary disease (COPD). PubMed, EMBASE, CENTRAL, Web of Science, Google Scholar, ICTRP, and ClinicalTrials.gov were searched. In adults with COPD that compared bacterial lysates with placebo or conventional COPD therapy. Primary outcomes were the effect of BLs on exacerbations and duration. Secondary outcomes were hospitalisation risk, the mean number of exacerbations per participant during trial follow up, symptom scores for dyspnoea, sputum, cough, and adverse events. We used random-effects meta-analysis, assessed risk of bias with Cochrane RoB 2, graded certainty with GRADE. Results Fifteen RCTs were included. The pooled risk ratio (RR) for exacerbation in patients with COPD treated with BLs vs. control was 0.83 (95% CI 0.74–0.93; P = 0.0009). The mean difference (MD) for exacerbation duration showed no statistical significant reduction −9.26 Days (95% CI −19.56 to 1.03; P = 0.08). Mean number of exacerbations (MD) −0.19 (95% CI −0.30 to −0.08; P = 0.0009). Hospitalisation RR was 0.52 (95% CI 0.35–0.78; P = 0.001).Symptom outcomes were dyspnoea standardised mean difference (SMD) −0.42 (95% CI −0.75 to −0.10; P = 0.01), cough (SMD) −0.37 (95% CI −0.63 to −0.11; P = 0.006), while sputum production showed no significant change (SMD) −0.20 (95% CI −0.65 to 0.25; P = 0.39), The RR for adverse events was 0.95 (95% CI 0.86–1.04; P = 0.27). Conclusion Bacterial lysates may be associated with lower COPD exacerbation and hospitalisation risk, with small numerical improvements in dyspnoea, cough, sputum production showed no significant improvement; effects varied by formulation, these findings require confirmation in formulation specific trials. Systematic Review registration https://www.crd.york.ac.uk/PROSPERO/view/CRD42024570783 , PROSPERO CRD42024570783.

chronic obstructive pulmonary diseasebacterial extractsCOPD exacerbationshospitalization
مراجعةمفتوح (مستودع)2026

Systemic lupus erythematosus in pregnancy: Maternal and fetal outcomes and management strategies (Review)

Medicine International · مجلد 6 (4) · 1-11

Systemic lupus erythematosus (SlE) is a chronic, multisystem, autoimmune disease that predominantly affects women during their reproductive years.Pregnancy in women with SlE is no longer considered uniformly prohibitive; however, it remains a high-risk clinical scenario due to maternal disease activity, lupus nephritis, antiphospholipid antibodies, chronic organ damage, and treatment-related factors that can adversely affect both maternal and fetal outcomes.Current evidence indicates that the risk of flare is highest in women who conceive with an active disease, discontinue effective therapy, or have a history of major organ involvement.at the same time, pregnancy introduces diagnostic complexity due to physiological gestational changes which may mimic lupus activity, particularly in hematological, renal and vascular domains.Maternal complications include preeclampsia, thromboembolism, infection, lupus nephritis exacerbation and postpartum flare, whereas fetal complications include miscarriage, fetal growth restriction, prematurity, neonatal lupus and congenital heart block in anti-ro/SSa-or anti-la/SSB-positive pregnancies.optimal management begins prior to conception and requires multidisciplinary care, risk stratification, medication optimization and structured maternal-fetal surveillance throughout pregnancy and the puerperium.the present narrative review summarizes contemporary evidence on the immunopathogenesis, preconception assessment, maternal and fetal risks, and therapeutic management of SlE in pregnancy, with an emphasis on clinically applicable strategies that improve patient outcomzes.Contents 1. Introduction 2. Pathogenesis of SlE 3. Effects of pregnancy on SlE 4. Pre-pregnancy counseling and considerations 5. Pre-pregnancy analyses in patients with SlE 6. Contraceptives in patients with SlE 7. Infertility in patients with SlE 8. Effects of SlE on pregnancy 9. Maternal complications associated with SlE 10.Placental disease in pregnancy in women with SlE and fetal complications of SlE 11.Puerperium 12. Medications for SlE during pregnancy 13.Biologics and emerging therapies 14.Conclusion

systemic lupus erythematosuspregnancymaternal complicationsfetal complications
مراجعةمفتوح (مستودع)20254استشهاد· Semantic Scholar

Efficacy and Safety of Dupilumab in Children With Moderate‐to‐Severe Asthma: A Systematic Review of Emerging Phase 3 Evidence

Pediatric Pulmonology · مجلد 60 (11) · e71391-e71391

BACKGROUND: Dupilumab is a human monoclonal antibody targeting the IL-4 receptor. There is a paucity of evidence regarding its efficacy and safety in pediatrics. Pediatric-specific data are limited, and most evidence comes from recent phase 3 trials and post hoc analyses. OBJECTIVE: To summarize the current evidence of the efficacy, safety, and biomarker effects of dupilumab in children with moderate-to-severe asthma, while identifying key gaps in the pediatric evidence base. METHODS: This study is a systematic review following PRISMA guidelines, and aims to assess the efficacy, safety, and biomarker response of dupilumab in pediatric patients with moderate to severe asthma. We evaluated the studies using the Cochrane Risk of Bias Tool 2.0. RESULTS: Six studies from 2021 to 2024 met the inclusion criteria: three of them are phase 3 randomized controlled trials and the other three post hoc analyses, mostly including children aged 6-11 years with type 2 inflammation, defined by elevated blood eosinophils and/or FeNO. Both allergic and nonallergic asthma phenotypes were represented across studies, with post hoc analyses indicating consistent benefit in each group. Dupilumab decreased the rate of severe exacerbations annually by 59.3% in children with type 2 inflammation. The study populations are mainly children between 6 and 11 years of age with moderate-to-severe asthma, characterized by eosinophilic or allergic phenotypes (type 2 asthma), including those with elevated blood eosinophils and/or FeNO levels. Dupilumab reduced the annual rate of severe exacerbation by ~59%, with greater reductions in children with FeNO ≥50 ppb (69%) or eosinophils ≥300 cells/µL (65%). The lung function showed improvement by 0.15-0.30 L in pre-bronchodilator FEV₁, accompanied by gains in asthma control and quality of life. Biomarker reductions (FeNO, eosinophils, IgE, TARC) were consistent across phenotypes. Adverse event rates were like placebo; eosinophilia and injection site reactions were more common but usually mild. CONCLUSION: This systematic review provides an early synthesis of emerging pediatric phase 3 evidence on dupilumab. While results suggest substantial benefits in reducing exacerbations, improving lung function, and modulating type 2 biomarkers, the evidence remains limited to short-term studies in a narrow age range. Longer-term follow-up, broader age representation, and real-world data are needed to define the long-term role of dupilumab in pediatric asthma. Prospero Code: CRD42024557750.

dupilumabchildhood asthmamoderate-to-severe asthmaIL-4 receptor alpha
مراجعةوصول مغلق20252استشهاد· Semantic Scholar

Impact of adenotonsillectomy on asthma control in children: a systematic review and meta-analysis of clinical outcomes

Journal of Asthma · مجلد 63 (1) · 1-14

Objective This study evaluated the impact of adenotonsillectomy on asthma symptoms in children by combining observational evidence with pooled analysis.Data sources We searched MEDLINE/PubMed, Cochrane Central Register of Controlled Trials, Web of Science, ProQuest, and Scopus from inception to March 17, 2025.Study selection Eligible studies assessed asthma outcomes in children undergoing adenotonsillectomy using retrospective or prospective cohort designs, case series, or database analyses. Eleven studies involving 74,204 participants were identified. Outcomes included asthma control scores (ACT/cACT), acute asthma exacerbations (AAEs), emergency department (ED) visits, oral corticosteroid use, hospitalization, inflammatory biomarkers, and atopic risk. Risk of bias was evaluated using ROBINS-I.Results Meta-analysis incorporated five studies with 52,479 participants. Adenotonsillectomy improved ACT/cACT scores by a mean of 2.5 points (95% CI:1.6–3.4; I2=0%), indicating better asthma control. A reduced risk of AAEs was observed (RD = 0.29; 95% CI:0.01–0.58), though with extreme heterogeneity (I2=100%). ED visits showed a small but significant reduction (MD=–0.01; 95% CI:0.00–0.02; I2=0%). Narrative synthesis found corticosteroid courses decreased by 23.7%, hospitalization rates fell by up to 35.8%, and patients reported improved quality of life and lower inflammatory biomarkers. However, most studies carried moderate to severe risk of bias due to confounding and selection issues.Conclusions Adenotonsillectomy may improve asthma control, reduce ED visits, and lessen medication use and hospitalization among children. Evidence regarding its effect on exacerbations remains inconsistent, and causality cannot be inferred due to reliance on observational data. Well-designed prospective controlled trials are needed to confirm effectiveness and clarify underlying mechanisms.

adenotonsillectomychildhood asthmaasthma controlacute asthma exacerbation
مراجعةوصول مفتوح2024292استشهاد· Semantic Scholar

Antibiotic action and resistance: updated review of mechanisms, spread, influencing factors, and alternative approaches for combating resistance

Frontiers in Pharmacology · مجلد 14 · 1305294-1305294

Antibiotics represent a frequently employed therapeutic modality for the management of bacterial infections across diverse domains, including human health, agriculture, livestock breeding, and fish farming. The efficacy of antibiotics relies on four distinct mechanisms of action, which are discussed in detail in this review, along with accompanying diagrammatic illustrations. Despite their effectiveness, antibiotic resistance has emerged as a significant challenge to treating bacterial infections. Bacteria have developed defense mechanisms against antibiotics, rendering them ineffective. This review delves into the specific mechanisms that bacteria have developed to resist antibiotics, with the help of diagrammatic illustrations. Antibiotic resistance can spread among bacteria through various routes, resulting in previously susceptible bacteria becoming antibiotic-resistant. Multiple factors contribute to the worsening crisis of antibiotic resistance, including human misuse of antibiotics. This review also emphasizes alternative solutions proposed to mitigate the exacerbation of antibiotic resistance.

antibiotic resistanceantibiotic mechanism of actionbacterial defense mechanismsspread of antibiotic resistance
مقالمفتوح (مستودع)2024

Effectiveness of TheraPEP Versus Conventional Breathing Techniques in Managing Acute COPD Exacerbations

International Journal of Physical Therapy Research & Practice · مجلد 3 (8) · 333-339

Background: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide, often complicated by acute exacerbations that impair lung function and quality of life. Effective airway clearance techniques are essential in managing exacerbations, but the comparative effectiveness of different methods remains unclear. This study aimed to evaluate the short-term effectiveness of TheraPEP, a positive expiratory pressure (PEP) device, versus the Active Cycle of Breathing Technique (ACBT) in managing acute COPD exacerbations. Methods: A randomized controlled trial (RCT) was conducted with 60 patients (≥40 years) admitted with acute exacerbations of COPD. Participants were randomly assigned to either the TheraPEP group (n=30) or the ACBT group (n=30). Each group received three daily sessions of their assigned therapy throughout their hospital stay. Primary outcomes included dyspnea, measured by the modified Borg Dyspnea Scale, and secondary outcomes included sputum clearance, lung function (FEV1, FVC, and FEV1/FVC ratio), oxygen saturation (SpO₂), and quality of life, measured by the Breathlessness, Cough, and Sputum Scale (BCSS). Data were collected at baseline, discharge, and 14-day follow-up. A two-way repeated-measures ANOVA was used to examine changes in dyspnea, lung function, sputum clearance, SpO₂, and BCSS scores over time (baseline, discharge, and 14-day follow-up) within and between groups. The main effects of time (within-subject factor) and group (between-subject factor) were assessed, along with the interaction effects (time × group). Results: Both groups demonstrated significant improvements in dyspnea, lung function, and quality of life from baseline to discharge and follow-up. However, the TheraPEP group showed significantly greater improvements in sputum clearance (p=0.01), oxygen saturation (p=0.03), and BCSS scores (p=0.03) compared to the ACBT group. No significant between-group differences were found for FEV1, FVC, or FEV1/FVC ratio (p > 0.05). Conclusions: Both TheraPEP and ACBT are effective in managing acute COPD exacerbations, but TheraPEP offers additional benefits in terms of sputum clearance and oxygenation. These findings suggest that TheraPEP may be more suitable for patients with severe mucus hypersecretion. Further research is warranted to assess the long-term effects of these therapies on COPD progression and patient outcomes.

positive expiratory pressureacute COPD exacerbationairway clearance techniquesactive cycle of breathing technique
مقالوصول مفتوح202223استشهاد· Semantic Scholar

Prevalence, Predictors and Point of View Toward Self-Medication Among Residents of Riyadh, Saudi Arabia: A Cross-Sectional Study

Frontiers in Public Health · مجلد 10 · 862301-862301

Irrational Self-Medication (SM) practice leads to incorrect diagnosis and is a risk factor for disease exacerbation and serious health consequences. Hence Responsible SM is vital for better health outcomes. In the present community-based study we explored the SM practice during the last 3 months, frequency, outcome, medications used, reasons influencing SM, source of the drug, and information. Data were analyzed using SPSS; chi-square test was performed to indicate significance, Odds ratio, Pearson correlation, univariant and multivariant regression analysis were performed to find out factors and predictors of SM. A total of 611 residents completed the survey. SM was practiced by 52.9% of participants during the last 3 months, with a frequency of one to two times. Headache (64.8%), pain (35.4%), fever/flu (31.4%), cold & cough (21.9%) and dysmenorrhea (20.9%) were illnesses managed using pain killers (75.9%), multivitamins (25.5%), anti-pyretic (24.7%) and herbal medicines (18.5%). Minor illness (67.9%), earlier experience (33.9%) and shortness of time to attend healthcare facilities (18.8%) were the reasons for practicing SM. Distance to healthcare and routine physical activity have significantly influenced the SM practice. Residents stated that inappropriate SM would lead to negative outcomes, including drug side effects (70%), Interaction (34.2%), poor treatment outcome (32.6%) and return of symptoms (26.5%). Interestingly, two-thirds of participants (68.9%) have recommended SM in case of minor illnesses only, 85.3% of respondents have expressed their desire to learn more about appropriate SM, and 76.6% are willing to return their leftover or unused medications to drug take-back centers.

self-medicationresponsible self-medicationadverse drug reactionsdrug interactions
مقالمفتوح (مستودع)2022

Effect of Primary Care on Reducing Rates of Hospitalization Among Chronic Obstructive Pulmonary Disease Patients

Journal of Healthcare Sciences · مجلد 02 (11) · 478-483

The normal course of Chronic obstructive pulmonary disease (COPD) includes a progressive reduction in lung function, exacerbations that necessitate primary care intervention or hospital admission, a steady decline in quality of life, and a shorter life expectancy. COPD is one of the ambulatory or primary care-sensitive illnesses for which it is hypothesized that efficient primary care management will lower the probability of hospital admission. Long-acting beta-agonist and inhaler steroid combination therapy improves spirometric results and overall health while lowering the annual risk of COPD exacerbations. Use of two or more treatment modules based on models designed specifically for chronic care delivery in developed countries have proven successful in lowering hospitalizations as well. Access to other therapies, such as pulmonary rehabilitation, acute exacerbation evaluation programs, and community or hospital-based respiratory specialists, may also be important. The goal of interventions to lessen the prevalence of COPD in underserved areas has to focus on locally driven integrated solutions, such as media campaigns to raise awareness and persuade at-risk individuals to get tested, as well as training for primary care workers on the significance and advantages of earlier detection and effective operation of chronic obstructive pulmonary disease. Importantly, uptake of influenza vaccination has demonstrated a link with hospital admission rates at the practice level. Proposed solutions for lowering hospitalization and reducing exacerbations among patients with COPD include greater access to pulmonary rehabilitative care, more rigorous implementation of smoking cessation programs and availability of modern long-acting medications.

chronic obstructive pulmonary diseasehospitalization ratesprimary careCOPD exacerbations
مقالوصول مفتوح20216استشهاد· Semantic Scholar

Bioinformatics analysis of rhinovirus capsid proteins VP1-4 sequences for cross-serotype vaccine development

Journal of Infection and Public Health · مجلد 14 (11) · 1603-1611

BACKGROUND: Rhinoviruses (RV) are associated with the development and exacerbations of asthma and chronic obstructive pulmonary disease. They've also been linked to more severe diseases like pneumonia, acute bronchiolitis, croup, and otitis media. Because of the hypervariable sequences in the same serotypes, no effective vaccine against rhinoviruses has been developed to date. With the availability of new full-length genome sequences for all RV-A and RV-B serotyped strains, this study used bioinformatics to find a suitable RV strain with the highest similarity matrices to the other strains. METHODS: The full genomic sequences of all known different RV-A and -B prototypes were downloaded from the National Centre for Biotechnology Information (NCBI) and divided into minor low-density lipoprotein receptor (LDLR) and major intercellular adhesion molecule groups (ICAM). The sequences were edited using Biological Sequence Alignment Editor, v 7.2.0 (BioEdit software) to study each capsid protein (VP1, VP2, VP3, and VP4) and analyzed using the EMBL-EBI ClustalW server and the more current Clustal Omega tool for the calculation of the identities and similarities. RESULTS: We analyzed and predicted immunogenic motifs from capsid proteins that are conserved across distinct RV serotypes using a bioinformatics technique. The amino acid sequences of VP3 were found to be the most varied, while VP4 was the most conserved protein among all RV-A and RV-B strains. Among all strains studied, RV-74 demonstrated the highest degree of homology to other strains and could be a potential genetic source for recombinant protein production. Nine highly conserved regions with a minimum length of 9-mers were identified, which could serve as potential immune targets against rhinoviruses. CONCLUSION: Therefore, bioinformatics analysis conducted in the current study has paved the way for the selection of immunogenic targets. Bioinformatically, the ideal strain's capsid protein is suggested to contain the most common RVs immunogenic sites.

rhinoviruscapsid proteinimmunogenic epitopesconserved domains